Production (Stage)
Appili Therapeutics Inc.
APLI.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 72.00K | 89.50K | 363.70K | 611.80K | 611.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 72.00K | 89.50K | 363.70K | 611.80K | 611.80K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 72.00K | 89.50K | 363.70K | 611.80K | 611.80K |
| SG&A Expenses | 2.05M | 1.98M | 2.12M | 2.23M | 2.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.33M | 7.37M | 7.58M | 6.96M | 6.58M |
| Operating Income | -7.26M | -7.28M | -7.22M | -6.34M | -5.97M |
| Income Before Tax | -1.91M | -2.90M | -2.62M | -2.77M | -2.76M |
| Income Tax Expenses | 13.10K | 400.00 | 12.00K | 42.40K | 51.70K |
| Earnings from Continuing Operations | -1.92 | -2.90 | -2.63 | -2.82 | -2.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.92M | -2.90M | -2.63M | -2.82M | -2.81M |
| EBIT | -7.26M | -7.28M | -7.22M | -6.34M | -5.97M |
| EBITDA | -7.25M | -7.27M | -7.21M | -6.33M | -5.96M |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 485.06M | 485.06M | 485.06M | 485.06M | 485.06M |
| Average Diluted Shares Outstanding | 485.06M | 485.06M | 485.06M | 485.06M | 485.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |